Leaders in Pharmaceutical Business Intelligence (LPBI) Group

News from Technion Integrated Cancer Center (TICC)

Reporter: Aviva Lev-Ari, PhD, RN

 

Technion Integrated Cancer Center, a first-of-its-kind institution that brings together world-class clinical experts, a group of life science researchers led by a Nobel Prize winner, and top-level chemists, physicists and engineers to win the battle against cancer.

The TICC serves as a nexus for the Technion’s five affiliated hospitals that run clinical trials, the Rappaport Faculty of Medicine’s life sciences researchers, the Faculty of Computer Science’s innovations in processing large data sets, the Viterbi Faculty of Electrical Engineering’s and the Faculty of Physics’ development of devices for diagnosis and imaging, and the Faculty of Mathematics’ search for new, more powerful algorithms to quickly and effectively process complex data.

The power of diverse, accomplished researchers and practitioners is essential to advancing our ability to combat cancer.

“We have quite a few ideas about how to combat this disease, but translating those ideas into actual drugs is not easy. We have to determine if the drugs work by finding the right patient population because not all patients will respond to certain drugs. And we need to develop new strategies to determine who those patients are,” Ronai said. “We used to develop the same drugs to attack cancer, but we now know that cancer is complex and heterogeneous. Our drugs need to be smart enough to attack the different elements of each different type of cancer.”

SOURCE

https://americantechniontoday.wordpress.com/2016/11/28/technion-integrated-cancer-center-ticc-turning-big-ideas-into-action/

Other related articles published in this Open Access Online Scientific Journal include the following:

Chapter 20: Cancer Research @Technion, Israel Institute of Technology

Stephen J. Williams, PhD

in

Series C: e-Books on Cancer & Oncology

VOLUME TWO 

Cancer Therapies:

Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

 

20.1 Recent Breakthroughs in Cancer Research at the Technion, Israel Institute of Technology, 2015

Stephen J. Williams, PhD

 

20.2 @Technion: Directions in Cancer Research

 

20.2.1 Medical Breakthrough: Israeli Researcher Predicts Where Cancer Will Spread

Evelina Cohn Budu, PhD

 

20.2.2 Pancreatic Cancer at the Crossroads of Metabolism

Demet Sag, PhD, CRA, GCP

 

20.2.3 List of Breakthroughs in Cancer Research and Oncology Drug Development by Awardees of The Israel Cancer Research Fund

Aviva Lev-Ari, PhD, RN

 

20.2.4 Cancer Labs at School of Medicine @ Technion: Janet and David Polak Cancer and Vascular Biology Research Center

Aviva Lev-Ari, PhD, RN

 

20.2.5 Immunity and Host Defense – A Bibliography of Research @Technion

Aviva Lev-Ari, PhD, RN

 

20.2.6 Host – Tumor Interactions during Cancer Therapy – Dr. Yuval Shaked’s Lab @Technion

Aviva Lev-Ari, PhD, RN

 

20.3 @Technion Deals, Partnerships, and Collaborations

 

20.3.1 Next-generation Universal Cell Immunotherapy startup Adicet Bio, Menlo Park, CA is launched with $51M Funding by OrbiMed

Aviva Lev-Ari, PhD, RN

 

20.3.2 Solutions for Multiple Myeloma – a cancer formed by Malignant Plasma Cells: Collaboration of NYU and Technion Integrative Cancer Center

Aviva Lev-Ari, PhD, RN

 

20.3.3 Biomarkers of Cancer detected by BreathAnalyzer – An Collaborative effort of three Universities

Aviva Lev-Ari, PhD, RN

 

20.3.4 Technion established the most advanced Center for Structural Biology in Israel

Aviva Lev-Ari, PhD, RN

 

20.3.5 Technion-Cornell Innovation Institute in NYC: Postdocs keep exclusive license to their IP and take a fixed dollar amount of Equity if the researchers create a Spinoff company

Aviva Lev-Ari, PhD, RN